|
|
|
| Application of modified Qinggan Huashi Huoxue Decoction combined with Polyene Phosphatidyl Choline in patients with alcoholic fatty liver |
| ZHANG Dong |
| Department of Infection,Chest Hospital of Jingzhou City,Hubei Province,Jingzhou 434000,China |
|
|
|
|
Abstract Objective To explore the application of modified Qinggan Huashi Huoxue Decoction combined with Polyene Phosphatidyl Choline in patients with alcoholic fatty liver.Methods A total of 200 patients with alcoholic fatty liver who were diagnosed and treated in Chest Hospital of Jingzhou City,Hubei Province from November 2017 to November 2019 were selected as the study objects.The patients were divided into the study group and the control group by random number table method,with 100 cases in each group.The control group was treated with Polyene Phosphatidyl Choline,and the study group was treated with modified Qinggan Huashi Huoxue Decoction on the basis of the control group.Therapeutic effect,liver function indexes(alanine aminotransferase[ALT],aspartate aminotransferase[AST]and γ-glutamine transpeptidase[GGT]),blood lipid level(total cholesterol[TC],triglyceride[TG]),serum fibrinogen protein 1(FLP1),type Ⅲprocollagen peptide(PⅢP)level were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of ALT,AST,GGT,TC and TG in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the FLP1 in the study group was higher than that in the control group,and the PⅢP was lower than that in the control group,the differences were statistically significant(P<0.05).Conclusion Modified Qinggan Huashi Huoxue Decoction combined with Polyene Phosphatidyl Choline is effective in the treatment of alcoholic fatty liver.It can obviously improve the metabolism of blood lipid and liver function,and reduce the degree of liver fibrosis.
|
|
|
|
|
|
| [1] |
谢佛添，王冬梅，吕翼.AMPK 信号通路在酒精性脂肪肝中的研究进展[J].中国细胞生物学学报，2020，42（7）：1221-1228.
|
| [2] |
赵金，潘道东，孙杨嬴，等.鹅肝酶解物对酒精性脂肪肝的改善作用[J].核农学报，2019，33（7）：1393-1398.
|
| [3] |
卜晓芬，李骏，朱虹.甘草甜素对体外诱导的酒精性脂肪肝细胞的影响及机制研究[J].重庆医学，2018，47（4）：436-438，445.
|
| [4] |
张波，李瑛.阿托伐他汀联合多烯磷脂酰胆碱治疗酒精性脂肪肝的效果[J].临床医学研究与实践，2018，3（35）：21-22.
|
| [5] |
肖玲辉，扈晓宇.退黄消脂方治疗酒精性脂肪性肝炎疗效观察[J].现代中西医结合杂志，2018，27（23）：2599-2600，2603.
|
| [6] |
肖达民，李丹青，吴艳华.酒精性肝病的中医临床研究进展[J].中药新药与临床药理，2018，29（1）：118-122.
|
| [7] |
杨柳，薄颖异，于冰莉，等.中医药防治酒精性肝病概况及相关机制研究进展[J].中成药，2020，42（3）：719-726.
|
| [8] |
中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南（2018 更新版）[J].中华肝脏病杂志，2018，26（3）：188-194.
|
| [9] |
邓铁涛.实用中医诊断学[M].上海：人民卫生出版社，1988.
|
| [10] |
国家中医药管理局.中医新药临床研究指导原则（试行）[S].北京：中国医药科技出版社，2002：29-31.
|
| [11] |
左志华，姜瑶，樊佳，等.MicroRNAs 在酒精性脂肪肝形成机制中的作用研究进展[J].解放军医学杂志，2020，45（3）：330-334.
|
| [12] |
杨建邦，王志.水飞蓟素联合多烯磷脂酰胆碱对酒精性脂肪肝患者的临床疗效[J].中成药，2019，41（6）：1469-1471.
|
| [13] |
Ma C，Zhang W，Yang X，et al.Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient micea new antiatherogenic strategy[J].Br J Pharmacol，2018，175（9）：1486-1503.
|
| [14] |
钟杰璋，陈贻威，潘家丽，等.中药治疗酒精性肝病的研究进展[J].世界中医药，2018，13（2）：504-507.
|
| [15] |
肖笃凯.健脾理气化浊方联合西药治疗酒精性脂肪肝（肝郁脾虚）随机平行对照研究[J].实用中医内科杂志，2018，32（2）：53-56.
|
| [16] |
姚志山，刘丁丁，云翔.清肝化湿活血汤联合保肝降酶药物治疗酒精性肝病的效果分析[J].临床肝胆病杂志，2016，32（8）：1557-1561.
|
| [17] |
陈美娟，黄海军，戴伊宁，等.血清纤维蛋白原样蛋白1与慢性乙型肝炎肝纤维化程度的相关性[J].国际流行病学传染病学杂志，2019，46（1）：47-50.
|
| [18] |
曹智丽，张文双，王维，等.还原型谷胱甘肽联合多烯磷脂酰胆碱治疗对酒精性肝病患者肝功能及肝纤维化指标的影响[J].广西医学，2017，39（3）：334-336.
|
|
|
|
